Roche stakes $2bn on UCB Alzheimer’s disease treatment
30-07-2020
Amgen and Roche target Samsung’s Bioepis in patent suit
01-05-2019
AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation
26-09-2018
Testing / Shutterstock.com
A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Roche, Amgen, drugs, cancer, biotech, Court of Appeals for the Federal Circuit
